Primary refractory disease in large B-cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial.
1/5 보강
OpenAlex 토픽 ·
Lymphoma Diagnosis and Treatment
Multiple and Secondary Primary Cancers
Cutaneous lymphoproliferative disorders research
APA
Inna Y Gong, John Kuruvilla, et al. (2026). Primary refractory disease in large B-cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial.. Blood advances, 10(7), 2249-2253. https://doi.org/10.1182/bloodadvances.2025018491
MLA
Inna Y Gong, et al.. "Primary refractory disease in large B-cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial.." Blood advances, vol. 10, no. 7, 2026, pp. 2249-2253.
PMID
41587423
같은 제1저자의 인용 많은 논문 (4)
- Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third-Line CAR T.
- Management of relapsed/refractory DLBCL in the era of novel agents and new approaches.
- Reporting and enrollment disparities in hematologic malignancy trials between 2000-2023.
- Disparities in clinical trial participation among older adult Medicare beneficiaries with hematologic malignancies from 2006 to 2019: A SEER-Medicare analysis.